Who Exports Verapamil from India — 135 Suppliers Behind a $110.6M Market
India's verapamil export market is supplied by 135 active exporters who collectively shipped $110.6M across 1,236 shipments. CADILA PHARMACEUTICALS LIMITED leads with a 60.7% market share, followed by MYLAN LABORATORIES LIMITED and ZYDUS LIFESCIENCES LIMITED. The top 5 suppliers together control 94.7% of total export value, reflecting a concentrated market structure.
Top Verapamil Exporters from India — Ranked by Export Value
CADILA PHARMACEUTICALS LIMITED is the leading verapamil exporter from India, holding a 60.7% share of the $110.6M market across 1,236 shipments from 135 exporters. The top 5 suppliers — CADILA PHARMACEUTICALS LIMITED, MYLAN LABORATORIES LIMITED, ZYDUS LIFESCIENCES LIMITED, GLENMARK PHARMACEUTICALS LIMITED, MICRO LABS LIMITED — collectively control 94.7% of total export value, indicating a highly concentrated market. Individual shares are: CADILA PHARMACEUTICALS LIMITED (60.7%), MYLAN LABORATORIES LIMITED (16.3%), ZYDUS LIFESCIENCES LIMITED (8.4%), GLENMARK PHARMACEUTICALS LIMITED (8.1%), MICRO LABS LIMITED (1.2%).
Top Verapamil Exporters from India
Ranked by export value · 135 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | CADILA PHARMACEUTICALS LIMITED PHARMACEUTICALS MEDICINES: VERAPAMIL HYD | $67.2M | 1 | 60.7% |
| 2 | MYLAN LABORATORIES LIMITED VERAPAMIL MYLAN PHARMA L P 240 MG 90BL TAB PACKS 13439HARMLESS MEDICINES, VERAPAMIL MYLAN PHARMA L.P. 240 MG 30BLPHARMACEUTICALS MEDICINES: VERAPAMIL HYD | $18.0M | 3 | 16.3% |
| 3 | ZYDUS LIFESCIENCES LIMITED PHARMACEUTICALS MEDICINES: VERAPAMIL HYD | $9.3M | 1 | 8.4% |
| 4 | GLENMARK PHARMACEUTICALS LIMITED PHARMACEUTICALS MEDICINES: VERAPAMIL HYD | $8.9M | 1 | 8.1% |
| 5 | MICRO LABS LIMITED PHARMACEUTICALS MEDICINES: VERAPAMIL HYDVERAPAMIL HYDROCHLORIDE INJECTION,5MG/2MVERAPAMIL HYDROCHLORIDE INJECTION USP, 5MG/2ML - 2ML | $1.3M | 3 | 1.2% |
| 6 | CAPLIN STERILES LIMITED PHARMACEUTICALS MEDICINES: VERAPAMIL HYDVERAPAMIL HYDROCHLORIDE INJECTION,5MG/2MVERAPAMIL HYDROCHLORIDE INJECTION USP, 5MG/2ML - 2ML | $1.1M | 3 | 1.0% |
| 7 | WATSON PHARMA PRIVATE LIMITED PHARMACEUTICALS MEDICINES: VERAPAMIL HYD | $966.6K | 1 | 0.9% |
| 8 | MANKIND PHARMA LIMITED PHARMACEUTICALS MEDICINES: VERAPAMIL HYD | $836.9K | 1 | 0.8% |
| 9 | EUGIA PHARMA SPECIALITIES LIMITED PHARMACEUTICALS MEDICINES: VERAPAMIL HYD | $456.0K | 1 | 0.4% |
| 10 | CADILA HEALTHCARE LTD PHARMACEUTICALS MEDICINES: VERAPAMIL HYD | $411.7K | 1 | 0.4% |
| 11 | STERIL-GENE LIFE SCIENCES PRIVATE LIMITED PHARMACEUTICALS MEDICINES: VERAPAMIL HYD | $341.0K | 1 | 0.3% |
| 12 | CADILA PHARMACEUTICALS LTD PHARMACEUTICALS MEDICINES: VERAPAMIL HYD | $186.0K | 1 | 0.2% |
| 13 | GLENMARK PHARMACEUTICALS LTD PHARMACEUTICALS MEDICINES: VERAPAMIL HYD | $142.9K | 1 | 0.1% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Verapamil exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Glenmark Pharmaceuticals Limited | Warning Letter, July 2025 | Unknown | Unknown | Unknown | FDA issued a warning letter citing CGMP violations at the Pithampur, Indore faci |
| Zydus Lifesciences Limited | Warning Letter, August 20 | Unknown | Unknown | Unknown | FDA issued a warning letter for CGMP violations at the Vadodara – Halol Highway |
| Eugia Pharma Specialities Limited | Warning Letter, August 20 | Unknown | Unknown | Unknown | FDA issued a warning letter citing CGMP violations at the Hyderabad facility. |
| Cadila Healthcare Limited | Warning Letter, October 2 | Unknown | Unknown | Unknown | FDA issued a warning letter for CGMP violations at the Moraiya, Ahmedabad facili |
| Cadila Pharmaceuticals Limited | Warning Letter, February | Yes, date unknown | Unknown | Unknown | FDA issued a warning letter citing CGMP violations at the Ankleshwar facility. |
| Cipla Limited | Warning Letter, November | Unknown | Unknown | Unknown | FDA issued a warning letter for CGMP violations at the Indore facility. |
TransData Nexus reviewed the regulatory standing of 6 leading Verapamil exporters from India. 0 hold US FDA facility approvals, 1 maintain WHO-GMP certification, and 0 are EU GMP compliant. 6 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Verapamil sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," contributes over 40% to the nation's bulk drug production. This prominence is supported by a robust infrastructure, including the Hyderabad Pharma City, which has been recognized as a National Investment Manufacturing Zone (NIMZ) since December 2019. The city's pharmaceutical landscape is characterized by numerous bulk drug manufacturers, such as A.R. Life Sciences, which specializes in active pharmaceutical ingredients (APIs) and intermediates. This concentration of API producers positions Hyderabad as a pivotal hub for sourcing Verapamil's raw materials.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Vadodara, in particular, hosts several large-scale pharmaceutical companies, including Alembic Pharmaceuticals, which manufactures and markets a range of pharmaceutical products, including APIs and formulations. The region's emphasis on formulations makes it a strategic location for the production of finished Verapamil products.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for India's pharmaceutical products. Mumbai, being a major port city, facilitates the export of pharmaceuticals to global markets. Companies like Formel Labs, with facilities in Mumbai, are committed to producing safe and effective medicines, ensuring that products like Verapamil meet international standards. The region's strategic location and established logistics infrastructure enhance the efficiency of Verapamil exports.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, largely due to favorable tax incentives. This area attracts numerous pharmaceutical companies seeking cost-effective production solutions. While specific data on Verapamil production in this cluster is limited, the region's overall manufacturing capabilities contribute to the broader pharmaceutical supply chain.
5Sourcing Recommendations
- Diversify Supplier Base: Given that the top five exporters account for 94.7% of Verapamil exports, it's advisable to diversify sourcing to mitigate risks associated with supplier concentration.
- Leverage Hyderabad's API Strength: Utilize Hyderabad's extensive API manufacturing capabilities to secure high-quality Verapamil raw materials.
- Engage with Gujarat's Formulation Experts: Collaborate with formulation specialists in the Ahmedabad-Vadodara region to develop and produce finished Verapamil products.
- Optimize Export Logistics via Mumbai: Utilize Mumbai's export infrastructure to streamline the distribution of Verapamil to international markets.
By strategically engaging with these pharmaceutical clusters, companies can enhance the efficiency and reliability of their Verapamil supply chain.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Verapamil exporters from India
Zydus Lifesciences Limited — Zydus acquires Agenus' CDMO business, expands biologics manufacturing
In June 2025, Zydus Lifesciences Limited acquired the contract development and manufacturing organization (CDMO) business of Agenus, including two biologics manufacturing sites in Emeryville and Berkeley. This acquisition aims to enhance Zydus' biologics manufacturing capabilities. IMPACT: The acquisition is not expected to directly impact Verapamil exports, as it focuses on biologics rather than small-molecule drugs like Verapamil.
Impact: The acquisition is not expected to directly impact Verapamil exports, as it focuses on biologics rather than small-molecule drugs like Verapamil.
Glenmark Pharmaceuticals Limited — Glenmark sells 75% stake in Glenmark Life Sciences to Nirma
In July 2024, Glenmark Pharmaceuticals Limited completed the sale of a 75% stake in its subsidiary, Glenmark Life Sciences, to Nirma Limited for approximately ₹5,651 crore. This strategic move was aimed at reducing debt and refocusing on core innovative pipelines. IMPACT: The divestment may lead to a reallocation of resources within Glenmark, potentially affecting the production and export strategies for Verapamil.
Impact: The divestment may lead to a reallocation of resources within Glenmark, potentially affecting the production and export strategies for Verapamil.
Glenmark Pharmaceuticals Limited — Glenmark transfers consumer care business to new subsidiary
In August 2025, Glenmark Pharmaceuticals announced the transfer of its consumer care business into a newly incorporated, wholly owned subsidiary named Glenmark Consumer Care Limited. This restructuring aims to segregate the marketing and trading of pharmaceutical and consumer care products. IMPACT: The restructuring is unlikely to have a direct impact on Verapamil exports, as it pertains to the consumer care segment rather than pharmaceutical manufacturing.
Impact: The restructuring is unlikely to have a direct impact on Verapamil exports, as it pertains to the consumer care segment rather than pharmaceutical manufacturing.
Common Questions — Verapamil Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which verapamil supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, CADILA PHARMACEUTICALS LIMITED leads with 50 recorded shipments worth $67.2M. MYLAN LABORATORIES LIMITED (96 shipments) and ZYDUS LIFESCIENCES LIMITED (42 shipments) are also established high-volume exporters.
Q How many verapamil manufacturers are there in India?
India has 135 active verapamil exporters with a combined export market of $110.6M across 1,236 shipments to 69 countries. The top 5 suppliers hold 94.7% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for verapamil from India?
Average FOB unit price: $11.32 per unit, ranging from $0.01 to $479.58. Average shipment value: $89.5K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 135 verified Indian exporters of Verapamil ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 1,236 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 69 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1,236 Verified Shipments
135 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists